LISBON, Portugal—For patients with nonvalvular A-fib, one of the major selling points for use of non-vitamin K antagonist oral anticoagulants (NOACs) over warfarin for stroke prophylaxis has been that ...

Patients with diabetes and a history of atrial fibrillation (AF) have fewer diabetic complications and lower mortality rates when prescribed non-vitamin K antagonist oral anticoagulants (NOACs) rather ...

Drugs work only when patients take them. That seems simple, but it is a core issue with the so-called novel or new oral anticoagulants (NOACs), which I prefer to call the non–vitamin-K oral ...

We are past the tipping point with the new oral anticoagulant drugs (NOACs), or direct oral anticoagulants (DOACs). Their dominance over warfarin has arrived. First is ease of use. These days everyone ...

Thromboembol in blood vessel. Clot formation, 3D illustration Experts review the current indications for NOACs as well as research on use as venous thromboembolism (VTE) prophylaxis in patients with ...

The main outcomes and measures were intraocular bleeding events and associated risk ratio for NOACs, compared with warfarin. Novel oral anticoagulants (NOACs) lead to a one-fifth reduction in the risk ...

Results from the FRAIL-AF study, being presented at the European Society of Cardiology 2023 Congress, surprised the investigators. In a study that will likely turn heads among cardiologists, findings ...

A retrospective cohort study of patients with atrial fibrillation and diabetes found that the use of non–vitamin K antagonist oral anticoagulants (NOAC) was associated with a lower risk of diabetes ...

Credit: Shutterstock. Updated guidelines also emphasize weight loss for overweight, obese patients with atrial fibrillation (HealthDay News) — For patients with atrial fibrillation, novel oral ...

A suggested benefit of the non-vitamin K antagonist oral anticoagulants (NOACs) is that they have fewer drug–drug interactions than warfarin. However, according to a retrospective cohort study ...

Non-vitamin K oral anticoagulants reduce hemorrhagic stroke and intracranial hemorrhage risks vs vitamin K antagonists in patients with end-stage renal disease and atrial fibrillation. Non-vitamin K ...

The use of NOACs expanded quickly into treatment and prophylaxis for recurrent VTE and prophylaxis of VTE following hip and knee replacement surgery. The dosing for this indication is different from ...